Eisai Inc. and Grupo Biotoscana Sign Exclusive Licensing Agreement for the Commercialization of Eisai's Oncology and Neurology Products throughout Latin America

WOODCLIFF LAKE, N.J. and MONTEVIDEO, Uruguay, Oct. 3, 2017 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo, Japan-based Eisai Co., Ltd., today announced that it has signed an agreement with Grupo Biotoscana (GBT) granting GBT the exclusive licensing rights to commercialize Eisai's Halaven® (eribulin mesylate), Lenvima® (lenvatinib), Fycompa® (perampanel) and Inovelon® (rufinamide) throughout Latin America. GBT will be responsible for obtaining and maintaining most marketing authorizations and any related regulatory and/or pricing approvals in the territory, with Eisai serving as the exclusive supplier of the products. In Mexico, however, Eisai will retain the rights to Halaven and Lenvima, and will seek to continue to build upon the growth of its oncology business in this country.

Eisai logo. (PRNewsFoto/Eisai Inc.)

"We are excited to collaborate with Grupo Biotoscana, a company with an extensive reach in the Latin American market," said Shaji Procida, President and COO of Eisai Inc. "This agreement will provide important therapeutic options for patients in need in a number of countries where they currently remain unavailable."

In addition to receiving compensation for supply of the products, Eisai is eligible to receive a one-time payment and certain financial milestone payments.

"We are honored to be partnering with Eisai, one of the leading research-based companies in the world, in order to help expand the usage of Halaven, Lenvima, Fycompa and Inovelon, four compounds that bring new hope for patients with debilitating diseases in Latin America," said Mariano García-Valiño, CEO of Grupo Biotoscana. "We are also excited to continue building on the success of Halaven and Lenvima in Brazil, as well as to expand the reach of Eisai's oncology and neurology products through future launches in Latin America. We believe this partnership will be key for GBT, and it reinforces our position as the partner of choice for cutting-edge medicines in Latin America."

Please see U.S. Prescribing Information for FYCOMPA, including BOXED WARNING, and the Medication Guide.

About Eisai Inc. 
At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.

Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at http://www.eisai.com/US and follow us on Twitter and LinkedIn.

About Eisai Co., Ltd. 
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

About Grupo Biotoscana 
Grupo Biotoscana (GBT) is a biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation and orphan/rare diseases, among others. GBT is currently present throughout 10 Latin American countries where it operates under its companies Biotoscana, United Medical and LKM. GBT's strong portfolio combines world-class licenses and proprietary products. GBT is controlled by a global private equity firm Advent International, with other significant shareholders including Essex Woodlands and several private investors.

To find out more about Grupo Biotoscana, please go to www.grupobiotoscana.com.

Media Inquiries

Investor Inquiries

Patricia Councill

Ivor Macleod

Eisai Inc.

Eisai Inc.




SOURCE Eisai Inc.

Type Press Release

Date Released October 03, 2017

May 9, 2022

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today...

Apr 26, 2022

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced an article about long-term health outcomes of its investigational anti-amyloid-beta (Aβ) protofibril antibody...

Apr 7, 2022

Eisai stands with people living with Alzheimer’s disease (AD), health care professionals and other members of our AD community. We respect that the Centers for Medicare and Medicaid Services...

Alerts - Release page
* Required Fields